Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

America braced for haemorrhagic dengue outbreak:

This article was originally published in Clinica

Executive Summary

Latin America is braced for a significant rise in the incidence of haemorrhagic dengue fever. Local reports of an increased incidence of the disease in several countries have prompted the health ministers of Bolivia, Colombia, Cuba, Ecuador, Peru and Venezuela to sign a co-operation agreement aimed at tackling the disease. Thirty-three new cases including four deaths, were recently confirmed in the Brazilian region of Ceara, where the previous annual record was 25 cases, recorded in 1994. At the end of May, Venezuela's epidemiological services were put on national alert in response to the recent rise in incidence of the disease (see Clinica No 960, p 11). At the beginning of June 2001, 3,037 cases of haemorrhagic dengue, including 28 deaths, were reported in the Americas, according to the Pan-American Health Organization; there were 205,841 cases of classic dengue.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT072185

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel